{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:36:22Z","timestamp":1777887382547,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,3]],"date-time":"2027-01-03T00:00:00Z","timestamp":1798934400000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ymgme.2025.109717","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T19:15:07Z","timestamp":1767208507000},"page":"109717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel promoters drive therapeutic transgene expression and evade transgene-specific immune responses in a mouse model of Pompe disease"],"prefix":"10.1016","volume":"147","author":[{"given":"Baodong","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Oh","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Eisner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwight D.","family":"Koeberl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2025.109717_bb0005","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0010","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2025.109717_bb0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine Pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0020","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2006.08.001","article-title":"Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II","volume":"14","author":"Sun","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0025","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/mt.2008.133","article-title":"Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy","volume":"16","author":"Sun","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0030","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/mt.2011.126","article-title":"Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector","volume":"19","author":"Luo","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0035","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41467-018-08283-7","article-title":"Next-generation muscle-directed gene therapy by in silico vector design","volume":"10","author":"Sarcar","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2025.109717_bb0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2016.03.006","article-title":"Salmeterol enhances the cardiac response to gene therapy in Pompe disease","volume":"118","author":"Han","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109717_bb0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymthe.2004.10.004","article-title":"Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II","volume":"11","author":"Sun","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0050","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1089\/hum.2011.063","article-title":"Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine Pompe disease","volume":"23","author":"Zhang","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.omtm.2019.11.020","article-title":"Comparisons of infant and adult mice reveal age effects for liver depot gene therapy in Pompe disease","volume":"17","author":"Han","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2025.109717_bb0060","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2002-09-2889","article-title":"Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway","volume":"102","author":"Davidoff","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2025.109717_bb0065","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/hum.2021.218","article-title":"Efficacious androgen hormone administration in combination with adeno-associated virus vector-mediated gene therapy in female mice with Pompe disease","volume":"33","author":"Han","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108559","article-title":"Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease","volume":"143","author":"Kishnani","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109717_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108608","article-title":"Home infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials","volume":"143","author":"Diaz-Manera","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109717_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109043","article-title":"Exploring the use of the national institutes of health toolbox cognition battery with children and adolescents with Pompe disease: preliminary findings","volume":"144","author":"Spiridigliozzi","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109717_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108119","article-title":"Severe cns involvement in a subset of long-term treated children with infantile-onset Pompe disease","volume":"141","author":"Kenney-Jung","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109717_bb0090","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMoa2407766","article-title":"Aav9-mediated gene therapy for infantile-onset Pompe's disease","volume":"392","author":"Ma","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2025.109717_bb0095","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ymthe.2005.01.012","article-title":"Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter","volume":"11","author":"Sun","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.omtm.2019.01.006","article-title":"Intravenous injection of an aav-php.B vector encoding human acid alpha-glucosidase rescues both muscle and CNS defects in murine Pompe disease","volume":"12","author":"Lim","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2025.109717_bb0105","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis IIIb in adult mice by rAAV9 trans-blood-brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0110","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1089\/hum.2016.099","article-title":"Systemic correction of murine glycogen storage disease type IV by an AAV-mediated gene therapy","volume":"28","author":"Yi","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.omtm.2018.11.002","article-title":"AAV gene transfer with tandem promoter design prevents anti-transgene immunity and provides persistent efficacy in neonate Pompe mice","volume":"12","author":"Colella","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2025.109717_bb0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jimd.12625","article-title":"Muscle-specific, liver-detargeted adeno-associated virus gene therapy rescues pompe phenotype in adult and neonate Gaa(-\/-) mice","volume":"47","author":"Sellier","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109717_bb0125","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ymthe.2018.06.023","article-title":"Correction of biochemical abnormalities and improved muscle function in a phase i\/ii clinical trial of clenbuterol in Pompe disease","volume":"26","author":"Koeberl","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0130","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I study of liver depot gene therapy in late-onset Pompe disease","volume":"31","author":"Smith","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ymgme.2019.10.005","article-title":"Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease","volume":"129","author":"Han","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109717_bb0140","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm.2019.05.56","article-title":"Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy","volume":"7","author":"Byrne","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymgme.2025.109717_bb0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","article-title":"Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy","volume":"123","author":"McIntosh","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109717_bb0150","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0155","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1089\/hum.2023.106","article-title":"Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 9 in a symptomatic mouse model","volume":"35","author":"Hayashi","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2025.109717_bb0160","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","article-title":"Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease","volume":"30","author":"Jeyakumar","year":"2023","journal-title":"Gene Ther."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225007097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225007097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:10:25Z","timestamp":1777608625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225007097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1096719225007097"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109717","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel promoters drive therapeutic transgene expression and evade transgene-specific immune responses in a mouse model of Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109717"}}